Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(03): 189-195
DOI: 10.4103/0971-5851.190356
ORIGINAL ARTICLE

Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables

Basharat Ahmad Kasana
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Waseem Raja Dar
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Sheikh Aijaz Aziz
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Abdul Rashid Lone
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Najeeb Ullah Sofi
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Imtiyaz Ahmad Dar
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Muzamil Latief
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Faheem Arshad
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Moomin Hussain
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
,
Mir Hussain
Department of Medicine, Oncology Division, Sher-i-Kashmir Institute of Medical Science, Soura, Jammu and Kashmir, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Introduction: Lung cancer is one of the most common causes of cancer deaths worldwide. Adenocarcinoma is taking over squamous cell lung cancer as the predominant histological subtype. Several cytotoxic drugs are available for the treatment of lung cancer, but side effects limit their use. Recently, targeted therapies for cancers have come into clinical practice. Aims and Objectives: To determine the prevalence of epidermal growth factor receptor (EGFR) mutation in adenocarcinoma lung in a North Indian population and its relation with different clinical variables. Materials and Methods: A total of 57 patients who met inclusion criteria were recruited into the study. Relevant history, clinical examination and investigations were done. EGFR mutation was done in all patients. Results: A total of twenty patients tested positive for EGFR mutation. EGFR was more frequently detected in female patients (53.8%), while as only 19.4% of the male patients expressed EGFR mutation, which was statistically very significant P = 0.007). EGFR mutation was more frequently detected in nonsmokers (52%) as compared to smokers (21.9%) which also was statistically significant P value of 0.018). EGFR mutation was more common in Stage III and IV adenocarcinomas (48%) as compared to Stage I and II (21.4%) which was statistically significant P value 0.034). Conclusion: EGFR mutation should be routinely done in all patients of adenocarcinoma lung particularly non-smoker females with Stage III and IV disease.

Keywords

Adenocarcinoma lung - epidermal growth factor receptor - geftinib


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Edelman MJ, Gandara DR. Lung Cancer. In: DA Casciato, BB Lowitz, editors. Manual of Clinical Oncology. 6th ed. Boston, New York Toronto, London: Little, Brown and Company, Publishers; 2008. p. 169-87.
  • 2 Minna JD, Schiller JH. Neoplasms of lung. Harrison's Principles of Internal Medicine. 17th ed. McGraw-Hill; 2008. p. 551. ISBN 0-07-146633-9.
  • 3 Nanda Kumar A. Consolidated Report of the Population Based Cancer Registries, Incidence and Distribution of Cancer. National Cancer Registry Programme; New Delhi; 1990-1996.
  • 4 Khan NA, Afroz F, Lone MM, Teli MA, Muzaffar M, Jan N. Profile of lung cancer in Kashmir, India: A five-year study. Indian J Chest Dis Allied Sci 2006;48:187-90.
  • 5 Whitrow MJ, Smith BJ, Pilotto LS, Pisaniello D, Nitschke M. Environmental exposure to carcinogens causing lung cancer: Epidemiological evidence from the medical literature. Respirology 2003;8:513-21.
  • 6 Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003;68:71-94.
  • 7 Brooks DR, Palmer JR, Strom BL, Rosenberg L. Menthol cigarettes and risk of lung cancer. Am J Epidemiol 2003;158:609-16.
  • 8 Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 2001;19:1734-42.
  • 9 Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
  • 10 Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-53.
  • 11 Travis WD, Bramvilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification (WHO) of Tumours. Lyon: IARCPress; 2004.
  • 12 Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29 5 Suppl 14:3-9.
  • 13 Bunn PA Jr., Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29 5 Suppl 14:38-44.
  • 14 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
  • 15 Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
  • 16 Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
  • 17 Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
  • 18 Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
  • 19 Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
  • 20 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80.
  • 21 Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004;64:8919-23.
  • 22 Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
  • 23 Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011;73:316-9.
  • 24 Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
  • 25 Qin BM, Chen X, Zhu JD, Pei DQ. Identification of EGFR kinase domain mutations among lung cancer patients in China: Implication for targeted cancer therapy. Cell Res 2005;15:212-7.
  • 26 Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
  • 27 Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005;11 (19 Pt 1):6816-22.
  • 28 Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005;93:355-63.
  • 29 Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
  • 30 Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54.
  • 31 Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012;23:1738-43.
  • 32 Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Grüning W, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): Routine screening data for central Europe from a cohort study. BMJ Open 2013;3. pii: E002560.
  • 33 Unal OU, Oztop I, Calibasi G, Baskin Y, Koca D, Demir N, et al. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. Asian Pac J Cancer Prev 2013;14:3705-9.
  • 34 Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
  • 35 Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
  • 36 Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23:159-68.
  • 37 Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62.
  • 38 Yang PC, Shi Y, Siu-Kie JA, Srinivasan S, Cornelio GH, Tsai CM, et al.. Molecular epidemiological prospective study of EGFR mutations from Asian patients with advanced lung adenocarcinoma (PIONEER). J Clin Oncol 2012;30:(Suppl; abstr 1534).
  • 39 Mehta J. Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population. Indian J Cancer 2013;50:102-6.
  • 40 Shankar S, Thanasekaran V, Dhanasekar T, Duvooru P. Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India. Lung India 2014;31:23-8.
  • 41 Pungliya M, Sachin M, Soumittra N, Shekar P, Shyam A. A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: Disparity between north and south Indian patients. J Cancer Ther Res 2014;3:4.